App-based self-administered biofeedback for the prevention of episodic migraine: A randomized controlled trial.

CephalalgiaAug 30, 2026 (epub)
Clinical ResearchNeurology

Amalie Christine Poole, Anker Stubberud, Melanie Rae Simpson et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the efficacy of an app-based biofeedback intervention for preventing episodic migraine in 279 adults. Participants using the biofeedback reported a reduction in monthly migraine days (MMDs) by 0.9 days compared to no change in the control group (P = 0.002). Additionally, quality of life improved significantly in the intervention group.

Key findings

  • Participants in the biofeedback group experienced a reduction in MMDs by 0.9 days compared to the control group.
  • The biofeedback intervention led to a mean improvement of 5.3 points in MSQ v2.1 total scores.
  • Nine mild device-related adverse events were reported during the study.

Why it matters

The findings suggest that app-based biofeedback can effectively reduce migraine frequency and enhance quality of life, providing a non-pharmacological option for migraine management.

Source

PubMed · PMID 42669793

Published in Cephalalgia. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.